Objectives: To evaluate the efficacy of carbetocin for the prevention of postpartum hemorrhage (PPH) and related events after vaginal or cesarean delivery. Methods: Medline, Scopus, Embase, and the Cochrane Library were searched in February 2018 using combinations of the relevant MeSH terms, keywords. Bibliographies of articles were also subjected to manual search for additional reports. Randomized studies comparing carbetocin to any other uterotonic agent in the management of cesarean and vaginal deliveries. Two reviewers independently extracted the data. A random-effects meta-analysis was used for quantitative synthesis. Also, Bayesian random-effect metaregression was used to estimate the posterior probabilities (PP) for benefit with carbetocin use. Results: After full-text review, 30 trials were included in the meta-analysis. Compared to oxytocin, carbetocin was associated with a reduced need for additional uterotonic use in women undergoing cesarean delivery (RR 0.43, 95% CI 0.30–0.59, I^2 = 71%, 3216 women, PP > 99.9%). Women at high risk of PPH delivering vaginally also had a reduced need for additional uterotonic use with carbetocin compared to oxytocin (RR 0.56, 95% CI 0.34–0.94, I^2 = 38%, 789 women, PP = 81.2%). The risk of postpartum blood transfusion (RR 0.57, 95% CI 0.33–0.96, I^2 = 0%, 1991 women, PP = 97.9%) was also less with carbetocin compared to oxytocin in high-risk women undergoing cesarean delivery. The risk of PPH was similar between carbetocin and other uterotonic agents for both cesarean (RR 0.69, 95% CI 0.45–1.05, I^2 = 27%, 2926 women, PP = 96.3%) and vaginal deliveries (RR 0.61, 95% CI 0.32–1.14, I^2 = 35%, 1515 women, PP = 88.9%). Carbetocin is effective in reducing the need for additional uterotonic use and postpartum blood transfusion in high-risk women undergoing Cesarean delivery.